MedPath

Micafungin

Generic Name
Micafungin
Brand Names
Mycamine
Drug Type
Small Molecule
Chemical Formula
C56H71N9O23S
CAS Number
235114-32-6
Unique Ingredient Identifier
R10H71BSWG

Overview

Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

Background

Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

Indication

Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis. Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Associated Conditions

  • Abscesses
  • Aspergillosis
  • Candidemia
  • Candidiasis
  • Esophageal Candidiasis
  • Fungal Infections
  • Fungal peritonitis caused by Candida
  • Acute disseminated Candidiasis

FDA Approved Products

Micafungin
Manufacturer:Par Pharmaceutical, Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2022/12/13
NDC:42023-229
Micafungin
Manufacturer:Sagent Pharmaceuticals
Route:INTRAVENOUS
Strength:100 mg in 5 mL
Approved: 2022/03/04
NDC:25021-191
Micafungin
Manufacturer:Xellia Pharmaceuticals USA LLC
Route:INTRAVENOUS
Strength:20 mg in 1 mL
Approved: 2022/07/25
NDC:70594-037
Micafungin
Manufacturer:Xellia Pharmaceuticals USA LLC
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2022/07/25
NDC:70594-036
Micafungin in Sodium Chloride
Manufacturer:Baxter Healthcare Corporation
Route:INTRAVENOUS
Strength:150 mg in 150 mL
Approved: 2023/09/29
NDC:0338-9055

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath